TB-500 + BPC-157

Source-reported examples · not treatment recommendations

Amount

TB-500: 1.25 mg per occasion; BPC-157: 0.25–0.5 mg per day

Frequency

TB-500 twice weekly for four weeks, then weekly; BPC-157 daily

Cycle / observation period

12 weeks

Route / research model

Subcutaneous

The separate-vial stack differs from the source’s premixed blend schedules. Its combination is not independently validated here.

Titration & progression

A dose range is not a titration schedule. No independently verified stepwise escalation has been established for this source-reported regimen.

Compare vial strengths here. A different vial size changes the available material, not the biological dose.

Diluent & formulation

Diluent compatibility is formulation-specific. A verified manufacturer instruction is still needed before bacteriostatic water or another diluent can be listed as suitable for this research material.

Separate vials: 5 mg + 5 mg. Each ingredient needs its own material total and formulation instructions. These are not premixed products.

Read the reconstitution guide →

Selected observations from the cited research. Each finding retains its study population, formulation and limitations.

Studies of individual ingredients do not establish the effects of this finished combination. Combination studies are identified explicitly below.

• A direct 2026 rat Achilles-repair experiment did not demonstrate an additional benefit from the combination. The result should remain attached to its model and tested materials. ^[1]
• A small retrospective knee-pain report included a BPC-157 plus TB4 subgroup. It relied on reported pain responses and did not establish that the pair was superior to a randomized comparator. ^[2]
• FDA's scientific assessment includes a report of adverse reactions after a BPC-157/TB-500 product. It does not provide a reliable incidence estimate or establish causation for a particular ingredient. ^[3]

Read the complete research profile →

No compound-specific affiliate destination is listed here yet. Browse the Vendors Index for the available supplier records and disclosed relationships.

Medical publications and supporting literature from the corresponding protocol bibliographies, combined across vial strengths. Supplier and commercial catalog references are excluded. Duplicate destinations appear once. Inclusion does not mean that a paper validates the reported dose, or that an ingredient study tests the finished blend.

Bibliography checked September 22, 2026: 12 entries mapped from 1 source page. Medical and supporting references are retained below; supplier entries are excluded.

1. Original experiment
2. Original report
3. FDA report discussion
4. Frontiers in Endocrinology (2021)Further reading · Listed in reference bibliography.
5. Annals of the New York Academy of SciencesFurther reading · Listed in reference bibliography.
6. Frontiers in Pharmacology (2022)Further reading · Listed in reference bibliography.
7. HSS Journal (2025)Further reading · Listed in reference bibliography.
8. Current Pharmaceutical Design (2018)Further reading · Listed in reference bibliography.
9. Journal of Orthopaedic Surgery and Research (2019)Further reading · Listed in reference bibliography.
10. CDC (2024)General guidance · Listed in reference bibliography.
11. NCBI Bookshelf (2023)Further reading · Listed in reference bibliography.
12. U.S. Food and Drug AdministrationRegulatory / product information · Listed in reference bibliography.
13. CDC (2023)No destination link supplied in the source bibliography.Further reading · Listed in reference bibliography.

Reported schedule reference: PeptideDosages.com. Research findings are summarized independently from the listed sources.